Biomarin Pharmaceuticals (BMRN)

$55.43 -0.14 (-0.25%)
Market Cap 10.64B
Revenue (ttm) 2.85B
Net Income (ttm) 426.86M
EPS (ttm) N/A
PE Ratio 15.06
Forward PE 14.94
Profit Margin 14.96%
Debt to Equity Ratio 0.00
Volume 2,361,400
Avg Vol 2,225,710
Day's Range N/A - N/A
Shares Out 192.02M
Stochastic %K 84%
Beta 0.33
Analysts Strong Sell
Price Target $95.64

Company Profile

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic pep...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 506 6700
Address:
770 Lindaro Street, San Rafael, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 1:04 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BMRN Current Share Price: $55.43 Contracts: $BMRN January 15, 2027 $58 Calls Scale in: $7.85- $9.60 Scale out: $12.21-$15.71 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 3 at 11:58 PM
Enter: $BMRN NOV 21 2025 $55 CALLS Buy in Price: $3.80 - $4.10 Take Profit: $5.78 Stop Bleeding: $3.61 ROI Potential: 41% Exit Within: 360 Minutes https://moneygroup.us/alerts
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 10:59 PM
$BMRN: Unusual Options Activity Alerted CALL flow observed 33x contracts at Strike price of $60 Exp on 01/15/2027 with Premium of $27K and showing BULLISH Sentiment
0 · Reply
DairyQueen505
DairyQueen505 Oct. 3 at 3:36 PM
$BMRN down, down, down the drain. 💩💩💩
0 · Reply
ConsistencySpike
ConsistencySpike Oct. 3 at 1:21 PM
$CPRT $BMRN $ADMA $NVNO
0 · Reply
twincam
twincam Oct. 3 at 12:17 AM
$BMRN BioMarin ($BMRN) is often flagged as a buyout candidate. With ~$2.5B in revenue and a rare disease + gene therapy pipeline (VOXZOGO, Vimizim, Brineura, ROCTAVIAN), a potential takeout could imply $100–115/share, with upside if bidding heats up.
1 · Reply
Batman_the_legend
Batman_the_legend Oct. 2 at 11:35 PM
$CRCL I had 500 shares, only have 150 left. I own $BMRN that I'm think of selling along with my $NNE & $UAMY to re buy a large CRCL position. Think we get a pullback in CRCL ?
1 · Reply
DairyQueen505
DairyQueen505 Oct. 2 at 7:18 PM
$BMRN closing red
1 · Reply
tradeitbetit
tradeitbetit Oct. 2 at 6:06 PM
$BMRN something cooking? Another fakeout? Volume is there…
0 · Reply
DairyQueen505
DairyQueen505 Oct. 2 at 4:34 PM
$BMRN no legs. This closes red.
1 · Reply
Latest News on BMRN
BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks

Sep 30, 2025, 7:01 AM EDT - 4 days ago

BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks

BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 4:46 PM EDT - 25 days ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

Sep 8, 2025, 1:56 PM EDT - 26 days ago

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

PTCT

BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting

Sep 8, 2025, 9:00 AM EDT - 26 days ago

BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

Sep 6, 2025, 11:05 AM EDT - 4 weeks ago

BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 4, 2025, 11:27 AM EDT - 4 weeks ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Sep 3, 2025, 3:32 PM EDT - 4 weeks ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

ARGX BBH CYTK IBB XBI

BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 11:01 AM EDT - 4 weeks ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript

BioMarin to Participate in Upcoming Investor Conferences

Aug 27, 2025, 9:00 AM EDT - 5 weeks ago

BioMarin to Participate in Upcoming Investor Conferences

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401

Aug 5, 2025, 4:20 PM EDT - 2 months ago

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401

INZY

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

Aug 5, 2025, 1:11 PM EDT - 2 months ago

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 11:04 PM EDT - 2 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

Aug 4, 2025, 4:02 PM EDT - 2 months ago

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

Aug 1, 2025, 9:00 AM EDT - 2 months ago

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET

Jul 22, 2025, 9:00 AM EDT - 2 months ago

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jul 7, 2025, 6:29 PM EDT - 3 months ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BBIO GILD INSM XBI

BioMarin Announces Completion of Acquisition of Inozyme

Jul 1, 2025, 8:45 AM EDT - 3 months ago

BioMarin Announces Completion of Acquisition of Inozyme

INZY

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

Jun 24, 2025, 9:00 AM EDT - 3 months ago

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

May 21, 2025, 5:56 PM EDT - 4 months ago

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

INZY

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

May 16, 2025, 7:30 AM EDT - 5 months ago

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

INZY

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

May 12, 2025, 9:05 AM EDT - 5 months ago

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:25 PM EDT - 5 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

May 1, 2025, 4:05 PM EDT - 5 months ago

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

Apr 17, 2025, 9:00 AM EDT - 6 months ago

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion

Apr 3, 2025, 3:37 PM EDT - 6 months ago

BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

Apr 2, 2025, 9:00 AM EDT - 6 months ago

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Mar 20, 2025, 9:00 AM EDT - 7 months ago

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

Feb 25, 2025, 9:00 AM EST - 7 months ago

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

Feb 24, 2025, 4:05 PM EST - 7 months ago

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

Why Is BioMarin Stock Trading Higher On Thursday?

Feb 20, 2025, 9:39 AM EST - 8 months ago

Why Is BioMarin Stock Trading Higher On Thursday?

BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 8:08 PM EST - 8 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

Feb 19, 2025, 4:05 PM EST - 8 months ago

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

Feb 5, 2025, 9:00 AM EST - 8 months ago

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

Jan 23, 2025, 10:42 AM EST - 9 months ago

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

Jan 13, 2025, 12:00 PM EST - 9 months ago

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

Jan 6, 2025, 8:30 AM EST - 9 months ago

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

Nov 21, 2024, 3:00 PM EST - 11 months ago

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

Nov 16, 2024, 10:45 AM EST - 11 months ago

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

BioMarin to Participate in Three Upcoming Investor Conferences

Nov 6, 2024, 8:00 AM EST - 11 months ago

BioMarin to Participate in Three Upcoming Investor Conferences

BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 8:26 PM EDT - 1 year ago

BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

Oct 29, 2024, 4:03 PM EDT - 1 year ago

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

Oct 16, 2024, 8:30 AM EDT - 1 year ago

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

3 Oversold Stocks with Big RSI Rebound Potential

Oct 8, 2024, 2:42 PM EDT - 1 year ago

3 Oversold Stocks with Big RSI Rebound Potential

ELV HUM

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

Sep 25, 2024, 3:50 PM EDT - 1 year ago

BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

Sep 18, 2024, 8:00 AM EDT - 1 year ago

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

Ascendis Challenges BioMarin, But Market Response Seems Excessive

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Ascendis Challenges BioMarin, But Market Response Seems Excessive

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

Sep 4, 2024, 1:00 PM EDT - 1 year ago

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time

Sep 4, 2024, 7:30 AM EDT - 1 year ago

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY

Aug 29, 2024, 8:00 AM EDT - 1 year ago

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY

BioMarin to reduce global workforce by about 225 employees

Aug 28, 2024, 5:32 PM EDT - 1 year ago

BioMarin to reduce global workforce by about 225 employees

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 1:04 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BMRN Current Share Price: $55.43 Contracts: $BMRN January 15, 2027 $58 Calls Scale in: $7.85- $9.60 Scale out: $12.21-$15.71 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 3 at 11:58 PM
Enter: $BMRN NOV 21 2025 $55 CALLS Buy in Price: $3.80 - $4.10 Take Profit: $5.78 Stop Bleeding: $3.61 ROI Potential: 41% Exit Within: 360 Minutes https://moneygroup.us/alerts
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 10:59 PM
$BMRN: Unusual Options Activity Alerted CALL flow observed 33x contracts at Strike price of $60 Exp on 01/15/2027 with Premium of $27K and showing BULLISH Sentiment
0 · Reply
DairyQueen505
DairyQueen505 Oct. 3 at 3:36 PM
$BMRN down, down, down the drain. 💩💩💩
0 · Reply
ConsistencySpike
ConsistencySpike Oct. 3 at 1:21 PM
$CPRT $BMRN $ADMA $NVNO
0 · Reply
twincam
twincam Oct. 3 at 12:17 AM
$BMRN BioMarin ($BMRN) is often flagged as a buyout candidate. With ~$2.5B in revenue and a rare disease + gene therapy pipeline (VOXZOGO, Vimizim, Brineura, ROCTAVIAN), a potential takeout could imply $100–115/share, with upside if bidding heats up.
1 · Reply
Batman_the_legend
Batman_the_legend Oct. 2 at 11:35 PM
$CRCL I had 500 shares, only have 150 left. I own $BMRN that I'm think of selling along with my $NNE & $UAMY to re buy a large CRCL position. Think we get a pullback in CRCL ?
1 · Reply
DairyQueen505
DairyQueen505 Oct. 2 at 7:18 PM
$BMRN closing red
1 · Reply
tradeitbetit
tradeitbetit Oct. 2 at 6:06 PM
$BMRN something cooking? Another fakeout? Volume is there…
0 · Reply
DairyQueen505
DairyQueen505 Oct. 2 at 4:34 PM
$BMRN no legs. This closes red.
1 · Reply
the1darkside
the1darkside Oct. 2 at 4:07 PM
$BMRN Started a small position today. Constantly beat estimates. Reasonable P/E. And I believe it to be oversold at this time. Average analyst target is much higher than current price. Earnings are forecast to grow 17.01% per year Earnings grew by 156% over the past year Trading at good value compared to peers and industry
0 · Reply
tradeitbetit
tradeitbetit Oct. 2 at 2:04 PM
$BMRN go back to this sentiment its reasonable
0 · Reply
OracleTrailblazer
OracleTrailblazer Oct. 2 at 1:55 PM
@THE_Monkey_Banana_Genius @Thelonius_Stonk $BMRN buying the weakness?
1 · Reply
DairyQueen505
DairyQueen505 Oct. 2 at 12:44 PM
$BMRN will retest lows. Then will go lower.
1 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 3:12 AM
$BMRN: Unusual Options Activity Alerted CALL flow observed 33x contracts at Strike price of $60 Exp on 01/15/2027 with Premium of $25K and showing NEUTRAL Sentiment
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 1 at 11:03 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BMRN Current Share Price: $54.86 Contracts: $BMRN January 15, 2027 $55 Calls Scale in: $9.50- $11.61 Scale out: $14.77-$18.99 Can Easily Capture: 60% ROI Blended DTE: 471 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Moneymike79
Moneymike79 Oct. 1 at 10:28 PM
$BMRN this has to hold 55!
0 · Reply
DairyQueen505
DairyQueen505 Oct. 1 at 6:12 PM
$BMRN lol the rest of pharma deep green this turd barely moves. $30 PT. 💩
0 · Reply
Thamb19
Thamb19 Oct. 1 at 3:05 PM
$BMRN No worries... Took my profit... Enjoy both bulls and bears. The people I trade with are experts. They dont fool around. I could have waited for 56.84 but I found another opportunity. Cya.
0 · Reply
DairyQueen505
DairyQueen505 Oct. 1 at 2:23 PM
$BMRN fading down to flat or negative for the day. Bulls so naive. 💩
0 · Reply
DairyQueen505
DairyQueen505 Oct. 1 at 2:18 PM
$BMRN just watch this will fizzle out and close flat for the day. 💩
0 · Reply
Thamb19
Thamb19 Oct. 1 at 2:09 PM
$BMRN $SPY $IWM $XBI Biomarin hit options expected move Numbers work.
0 · Reply